Lundbeck's Study Shows Cognitive Improvement in Migraine Patients Using VYEPTI
Lundbeck has presented new data from the INFUSE study at the American Academy of Neurology 2026 Annual Meeting, highlighting improvements in cognitive symptoms among migraine patients treated with VYEPTI (eptinezumab-jjmr). The study observed patient-reported outcomes over six months, focusing on cognitive issues like brain fog and decision-making difficulties. The findings indicate that more than 50% of participants reported improvements in these symptoms after receiving VYEPTI, a preventive migraine treatment administered via IV infusion. The study emphasizes the importance of addressing the broader burden of migraine, beyond just headache frequency, to improve patients' quality of life. 
